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Abbreviations: 
AIH – Autoimmune Hepatitis 
ANA  – Anti-neutrophil Antibody 
AST  – Aspartate Aminotransferase 
CXCL10 – C-X-C Motif Chemokine Ligand 10 
FOXP3 – Forkhead-box-P3 
IgG – Immunoglobulin G 
IL-2 – Interleukin-2 
IL-10 – Interleukin-10 
IP-10 – Interferon-Inducible Protein-10 
IQR – Interquartile Range 
LDIL-2 – Low Dose Interleukin-2 
MFI – Mean Fluorescence Intensity 
MMF – Mycophenolate Mofetil 
pSTAT5 – Phosphorylated Signal Transducer and Activator of Transcription-5 
SEM  – Standard Error of Mean 
SLA  – Anti-Soluble Liver Antigen 
SMA – Anti-Smooth Muscle Antibody 
Tcon – CD4+CD25-FoxP3- T Conventional Cell 
Treg – CD4+CD25+Fopx3+ T Regulatory Cell 
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INTRODUCTION 
The management of autoimmune hepatitis (AIH) has largely remained 
unchanged for the past three decades. The optimal regimen for patients who do 
not respond to first-line treatment of corticosteroids with-or-without 
azathioprine remains unclear.  There is growing interest in the use of 
immunotherapies targeting CD4+Forkhead-box-P3(Foxp3)+ regulatory T-cells 
(Tregs). Tregs are a T-lymphocyte sub-population with immunosuppressive and 
cytoprotective capacity that play a key role in restraining auto-reactive 
conventional T-lymphocytes (Tcons) and preventing autoimmunity. Due to their 
constitutive expression of CD25, the alpha-chain of the interleukin-2-receptor, 
Tregs are highly dependent on, and exquisitely sensitive to, IL-2.(1) The use of 
low-dose IL-2 (LDIL-2) as an immunomodulatory agent is being explored in 
various autoimmune disorders.(2) We report here the clinical and 
immunological effects of LDIL-2 in two patients with refractory AIH. 
 
Patients 
Patient-1 had previously required repeated intravenous corticosteroid courses 
for AIH flares despite triple therapy. Patient-2 was intolerant to azathioprine, 
had suffered multiple flares whilst on MMF and prednisolone, and refused 
initiating Tacrolimus due to long-term toxicity concerns. Both patients had 
persistent disease activity as assessed by serum biochemistry and a liver biopsy 
performed within the previous 12months (Table_1). IL-2 (Proleukin, Novartis 
Pharmaceuticals UK) was administered as 1million IU subcutaneous injections 
for 5 consecutive days monthly, for 6months. Patients gave written informed 
consent to receive LDIL-2 under a clinical protocol approved by King’s Medicines 
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Management Committee, and to participate in an immunomonitoring study 
(REC15/NS/0062) involving collection of sequential peripheral blood samples. 
Patient-1 experienced no significant changes in aspartate aminotransferase 
(AST) and immunoglobulin-G (IgG) levels between baseline and end-of-
treatment. Conversely, in patient-2 both AST and IgG levels decreased to within 
the normal range by end-of-treatment (Table_1 and Fig.1A). No adverse events 
other than rapidly resolving mild injection-site reactions were observed. 
The proportion of circulating Tregs increased significantly in both patients by 
day-4 after each cycle of LDIL-2, peaking at day-9, and returned to baseline 
values at day-28 (Fig.1B). The changes in Tregs were due to increases in the 
proportion of resting (CD45RA+FOXP3lo) and effector Tregs (CD45RA-FOXP3hi), 
with no significant changes in the cytokine-secreting, non-suppressive CD45RA-
FOXP3lo subset (Sup_Fig.1A-B). LDIL-2 therapy also resulted in increases in 
soluble CD25, Treg proliferation (as assessed by Ki-67), and in the Treg 
expression of CD25 and FOXP3 (considered surrogate markers of suppressive 
capacity) (Sup_Figs.1C-E, 3B & 5F-G). We measured intra-cellular pSTAT5 to 
assess the IL-2 Treg sensitivity. At baseline, Tregs from both patients exhibited 
lower pSTAT5 levels than those from age-matched healthy controls, but this was 
normalized following LDIL-2 therapy (Fig.1D).  
 
DISCUSSION 
We provide here what to the best of our knowledge is the first evidence 
suggesting that administration of LDIL-2 to AIH patients is safe and effective in 
increasing the pool of circulating Tregs. While we observed a consistent increase 
in Tregs following LDIL-2 therapy, this effect was of shorter duration and lower 
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magnitude than that reported in patients receiving higher and/or more frequent 
doses (1-3millionIU/day),(2) suggesting these alternative regimens might be 
preferable to sustain the expanded Treg pool. Of note, LDIL-2 treatment 
increased the IL-2 sensitivity of Tregs and corrected the suboptimal pSTAT5 
response recently described as being a hallmark of AIH.(3) Importantly, the 
effects of LDIL-2 were restricted to Tregs, as we detected no significant changes 
in non-Treg immune cell subsets  (Fig.1C and Supplementary Results). Animal 
data indicate that intra-hepatic Treg expansion is compromised in the presence 
of severe liver damage.(4) This could account for patient-1 lack of clinical 
response. 
In conclusion, our observations demonstrate the feasibility of using LDIL-2 to 
improve inflammatory liver damage by increasing the pool of immunoregulatory 
lymphocytes. Our data provide rationale and a proof-of-principle to further 
explore the clinical use of LDIL-2 in the management of autoimmune liver 
diseases.   
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Table 1. Clinical characteristics of the 2 patients receiving low-dose interleukin-2 
(LDIL-2) treatment. Baseline serum tests were taken prior to initiating LDIL-2 
treatment, whilst end of treatment was taken at 3 months following completion 
of last (sixth) cycle of LDIL-2 treatment. 
 
 
Patient Characteristics Patient-1 Patient-2 
Age (years) 20 56 
Sex Female Female 
Age at diagnosis (years) 13 51 
Duration of disease (years) 7 5 
Serology SMA+ (1/160) ANA+ (1/40) 
Anti-SLA + 
IAIHG Score 8 9 
Immunosuppression at baseline Tacrolimus 1mg OD 
MMF 1g BD 
Prednisolone 15mg OD 
MMF 1g BD 
Prednisolone 15mg OD 
Liver histology Severe autoimmune 
hepatitis with cirrhosis 
Moderate chronic 
hepatitis with interface 
activity and focal 
bridging fibrosis 
Baseline serum tests (normal 
range) 
• AST (10-50 IU/ml) 
• Globulin (25-35 g/l) 
• Immunoglobulin G (6.3-18.1 g/l) 
• Albumin (35-50 g/l) 
• Bilirubin (3-20 μmol/l) 
• Platelet (150-450 x 109/l) 
• INR (0.90-1.20) 
 
 
149 
53 
29.4 
42 
40 
152 
1.17 
 
 
259 
43 
20.9 
44 
14 
198 
1.11 
Serum tests at end-of-treatment 
• AST (10-50 IU/ml) 
• Globulin (25-35 g/l) 
• Immunoglobulin G (6.3-18.1 g/l) 
• Albumin (35-50 g/l) 
• Bilirubin (3-20 μmol/l) 
• Platelet (150-450 x 109/l) 
• INR (0.90-1.20) 
 
174 
49 
30.2 
37 
33 
132 
1.07 
 
44 
33 
16.2 
41 
55 
191 
1.06 
*SMA – smooth muscle antibodies, ANA – anti-neutrophil antibody, Anti-SLA – 
anti-soluble liver antigen, MMF – Mycophenolate mofetil, AST – aspartate 
aminotransferase, OD – Once Daily, BD – bis die/twice daily, INR – International 
Normalised Ratio. 
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Fig. 1. Effect of low-dose interleukin-2 (LDIL-2) 5-day treatment cycles, 
(depicted in grey shade) on serum biochemistry and circulating 
CD4+CD25+FoxP3+ regulatory T-cells (Tregs). (A) Sequential changes in 
serum AST levels during the 6 cycles of LDIL-2 treatment for each patient. (B) 
Proportion of Tregs before and after each of the cycles of LDIL-2 treatment.. (C) 
Changes in the proportion of Tregs,  conventional T-cells (Tcons) and  natural 
killer (NK) cells after combining the data from the 12 cycles of LDIL-2 treatment 
from both patients (data show mean and standard error of mean, SEM, * = p-
value <0.05, ** = p-value <0.005).  (D) Sensitivity to IL-2 of circulating Tregs 
collected before and at different time points after initiating LDIL-2. The response 
to IL-2 was assessed by measuring in Tregs the mean fluorescence intensity of 
intracellular pSTAT5 (pSTAT5 MFI; y-axis) by flow cytomery following ex vivo 
stimulation with increasing concentrations of IL-2 (x-axis). Data shown 
correspond to 3 healthy controls and 2 patients and are expressed as mean ± 
SEM. 
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